Sleep Disorders

SLEEP 2026: GLP-related home sleep testing made up 44% of primary care referrals, but many studies were negative or suboptimal, according to a late-breaking abstract.

SLEEP 2026: Virend Somers, MD, of Mayo Clinic, outlines why sleep has been added to the AHA's Life’s Essential 8.

Laura B. Herpel, MD, reviews REFRESH trial data on once-nightly oxybate in narcolepsy, focusing on daytime function, stimulant reduction, and mental health.

Patil reviews 3 new AASM guidelines at SLEEP 2026 covering updated CSA treatment, first-ever inpatient OSA guidance, and chronic insomnia therapy hierarchy.

Andrew Ho, MD, reviews single-center data showing GLP-1 coverage barriers reshaped OSA referral patterns, with symptom documentation absent in most cases.

SLEEP 2026: In an 8-week randomized trial, reishi mushroom extract reduced Insomnia Severity Index scores more than melatonin in adults with chronic insomnia.

Baker explains how smartwatch sleep data can open clinical conversations about menopausal sleep disturbance but emphasizes the importance of patient-reported outcomes.

SLEEP 2026: New long-term data showed pitolisant was generally well tolerated and improved symptoms in adults with idiopathic hypersomnia.

SLEEP 2026: Residual cataplexy affected 76.8% of treated adults with narcolepsy type 1 and was linked to greater symptom burden and poorer quality of life.

A 28-day smartwatch study in menopausal women found sleep fragmentation varied from night to night while total sleep time remained stable.

Wearable sleep tracker use was linked to better sleep in patients with insomnia and COMISA, while OSA showed a divergent pattern warranting further study.

Mander highlights sleep as a modifiable dementia risk factor, emphasizing sleep apnea diagnosis and treatment to support brain health.

Emerging data link sleep disorder severity to Alzheimer's biomarker accumulation, with small CPAP studies suggesting partial biomarker reversibility with treatment.

Prenatal sleep expectations predicted postpartum sleep quality above parity and psychiatric history, with postpartum anxiety further worsening outcomes.

Pauline Maki, PhD, reviews data showing over half of elinzanetant's sleep benefit in postmenopausal women is independent of VMS reduction.

From behavioral therapy to NK3 receptor antagonists, Baker outlines an expanding toolkit for menopausal sleep disturbance.

Baker discusses menopause-related sleep disturbances and why early screening and individualized treatment are critical in primary care.

High-risk rural patients were less likely than urban patients to be referred for obstructive sleep apnea evaluation in primary care.

New research suggests EDS combined with prolonged sleep-onset latency is linked to 3x greater risk of incident hypertension and 2x greater risk of prevalent hypertension.

AD109 reduced apnea-hypopnea index versus placebo in a phase 3 trial of adults with OSA unable or unwilling to use CPAP.

Late-breaking SLEEP 2026 findings bring primary-care-ready insights on insomnia drugs, sleep apnea genetics, menopausal sleep, and GLP-1 links.

SLEEP 2026: Women with moderate-to-severe obstructive sleep apnea reported worse sleep, fatigue, anxiety, headaches, and nocturia than men.

ACOG 2026: In a nationally representative survey, 75% of women with menopausal symptoms reported sleep problems vs 49.8% without symptoms.

Your daily dose of the clinical news you may have missed.

A new review examines whether neuromodulation techniques may help address excessive daytime sleepiness across neurologic and psychiatric conditions.